ACTing with Mindfulness for Pain (AMP): A pilot randomized controlled trial of an integrated acceptance and commitment therapy and mindfulness meditation program.
M. Herbert, J. Fishbein, Mara Tynan, E. Martínez, Ariel J Lang, Pollyanna Casmar, A. Higdon, Autumn Backhaus, Shahrokh Golshan, Niloofar Afari
Behaviour Research and Therapy September 1, 2025 DOI: 10.1016/j.brat.2025.104854 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Pilot randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 87 |
| Population | Veterans with chronic pain |
| Intervention | Cognitive behavioral therapy (CBT) |
| Duration | Posttreatment and 3-month follow-up |
| Measures | pain interference, pain acceptance, cognitive defusion, pain catastrophizing, depressive symptoms, pain-related helplessness |
| Topics | Meditation |
| Key findings | Both AMP and CBT produced significant within-group improvements in pain interference, pain acceptance, and pain catastrophizing at posttreatment, with reduced effects at three months. In the AMP group, home meditation practice was dose-dependently associated with greater reductions in depressive symptoms and pain-related helplessness. Feasibility was supported, but effect sizes indicate further treatment development is needed. |
Abstract
Acceptance and commitment therapy (ACT) is an empirically-supported psychotherapy for chronic pain. Although mindfulness is a key component of ACT, most ACT protocols do not include formal mindfulness meditation practice as a principal treatment method, leaving open the question of whether formal practice may bolster ACT's effects. Addressing this gap, the present study assessed the feasibility and preliminary treatment effects of ACTing with Mindfulness for Pain (AMP), an ACT-based protocol that emphasizes and measures daily formal mindfulness meditation practice. A total of 87 Veterans (Mage = 49.44, SD = 12.42) were randomized to AMP or cognitive behavioral therapy (CBT). Feasibility was supported by attainment of enrollment targets, achievement of retention rates at post-treatment greater than 80 %, and high levels of treatment credibility and satisfaction. Treatment expectancy was lower than hypothesized in both groups. Within the AMP group, there were significant improvements in pain interference (primary outcome; d = -0.58), pain acceptance (d = 0.72), cognitive defusion (d = 0.23) and pain catastrophizing (d = -0.50) at posttreatment. Within the CBT group, there were significant improvements in pain interference (d = -0.59), pain acceptance (d = 0.50), and pain catastrophizing (d = -0.39) at posttreatment. In both groups, effect sizes were reduced at 3-month follow-up. Home meditation practice was dose-dependently associated with a greater reduction of depressive symptoms and pain-related helplessness in the AMP group. Taken together, despite meeting important feasibility metrics, the effect size estimates from this pilot randomized controlled trial highlight the need for further treatment development before moving to formal efficacy evaluation.